LFMT vs Placebo in New Biologic Start for Ulcerative Colitis
NCT05327790
Recruiting
To compare the safety and efficacy of concomitant LFMT versus placebo in UC patients who are starting vedolizumab or ustekinumab.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/02/2025
Locations: University of Alberta Hospital, Edmonton, Alberta
Conditions: Ulcerative Colitis
Register for Updates
rTMS for Apathy Clinical Trial
NCT05561205
Recruiting
Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in neurocognitive disorders and mild behavioural impairment in individuals receiv... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/02/2025
Locations: Sunnybrook Health Sciences Centre, Toronto, Ontario
Conditions: Alzheimer Disease, Apathy in Dementia, Dementia, Mild Behavioural Impairment, Mild Cognitive Impairment, Neurocognitive Disorders
Register for Updates
Ketone Monoester Supplements, High Altitude, and Brain Blood Flow During Exercise
NCT07063732
Recruiting
The purpose of this trial is to investigate the effect of acute ketone monoester ingestion (0.6 g KME/kg body weight) on the occurrence of the ventilatory threshold and the subsequent response of blood velocity in cerebral arteries during a maximal exercise test at low altitude and high altitude.
Gender:
ALL
Ages:
Between 18 years and 35 years
Trial Updated:
07/02/2025
Locations: Barcroft Research Station, Bishop, California +1 locations
Conditions: High Altitude Hypoxia, Exercise
Register for Updates
Comparing Cardiac Chamber Measurements: TTE vs. TEE Under Anesthesia
NCT06715371
Recruiting
This study aims to compare two common ultrasound techniques used during heart surgery: transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE). TTE is performed by placing an ultrasound probe on the chest, while TEE involves inserting a probe into the esophagus, which provides closer and clearer images of the heart. Both methods are part of routine care for patients undergoing heart surgery. The goal of this study is to assess how well the measurements from TTE and TEE a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Sunnybrook Health Sciences Centre, Toronto, Ontario
Conditions: Heart Chambers
Register for Updates
Be Sweet to Babies During Nasolaryngoscopy
NCT06641687
Recruiting
The investigators want to know if sugar water containing 24% sucrose is helpful in reducing pain in babies during scopes.
Gender:
ALL
Ages:
Between 1 month and 12 months
Trial Updated:
07/02/2025
Locations: The Hospital for Sick Children, Toronto, Ontario
Conditions: Infant Conditions
Register for Updates
Acoustics as a Metric of Airway Pressure in Premature Infants Using Bubble Continuous Positive Airway Pressure
NCT07060833
Recruiting
This is an observational, proof-of-concept, feasibility study where 30 preterm infants on bubble CPAP with gestational age \< 32+0 weeks will be recruited from the neonatal intensive care unit (NICU) at the Montreal Children's Hospital. The study's main goals are: 1. To determine the relationship between ambient bubbling sounds and delivered pressures in preterm infants on bCPAP. 2. To determine the relationship between transmitted bubbling sounds and airway pressures transmitted to the lungs... Read More
Gender:
ALL
Ages:
Between 28 weeks and 32 weeks
Trial Updated:
07/02/2025
Locations: McGill University Health Center, Montreal, Quebec
Conditions: Preterm Infant
Register for Updates
Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy
NCT06989541
Recruiting
Chimeric antigen receptor (CAR) T cells are special immune cells taken from a patient and changed in a lab to help them find and attack cancer cells. These cells are designed to look for a marker called CD19, which is found on both cancer cells and healthy B cells (a type of white blood cell). Because of this, CAR T cells can also destroy healthy B cells. This can lead to a strong drop in B cells and cause a condition called hypogammaglobulinemia (HGG), which makes it harder for the body to figh... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: University of Alberta, Edmonton, Alberta
Conditions: Hypogammaglobulinemia, Acquired
Register for Updates
PSMA-Guided Ablation of the Prostate
NCT06003556
Recruiting
The goal of this phase 2 multicenter randomized controlled trial is to study the accuracy of second generation prostate specific membrane antigen (PSMA) positron emission tomography (PET; utilizing 18F-PSMA-1007) compared to standard of care multiparametric MRI and MRI targeted-prostate biopsy for staging in patients diagnosed with unilateral prostate cancer who are eligible for focal therapy. The main question it aims to answer is: Can PSMA PET improve diagnostic accuracy for the primary stag... Read More
Gender:
MALE
Ages:
50 years and above
Trial Updated:
07/02/2025
Locations: Prostate Cancer Centre, Calgary, Alberta +2 locations
Conditions: Prostate Cancer, Localized Prostate Carcinoma
Register for Updates
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Birmingham, Alabama +723 locations
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399
Recruiting
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occu... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
07/01/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +207 locations
Conditions: Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Register for Updates
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
NCT05938270
Recruiting
A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Research Site, Detroit, Michigan +18 locations
Conditions: Prostate Cancer
Register for Updates
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475
Recruiting
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/01/2025
Locations: Helios Clinical Research - Phoenix, Phoenix, Arizona +55 locations
Conditions: Type 2 Diabetes
Register for Updates